Navigation Links
Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients
Date:8/31/2010

SAN DIEGO, Aug. 31 /PRNewswire/ -- Sangart, Inc., today announced positive results from its Phase IIa proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis. The study demonstrated that MP4OX, when given in addition to standard of care, was effective at decreasing lactate levels in treated patients. During hemorrhagic shock, inadequate perfusion of critical organs can lead to insufficient oxygenation of tissues, which can be detected by an increase in lactate levels. MP4OX is a novel oxygen therapeutic agent that is designed to provide rapid oxygen delivery to ischemic tissues.

Study data show a statistically significant greater immediate and sustained decrease of lactic acid in patients treated with MP4OX compared to patients in the control group. The study also found that a greater proportion of patients treated with MP4OX were able to attain normal lactate levels as early as four hours post-treatment. Furthermore, data demonstrated a strong trend toward outcomes benefits through multiple measures, including reducing the average total number of days patients spent in hospital. In patients treated with MP4OX, the median hospital stay was half that of the control group. Serious adverse events were of equal rates and similar in nature between the MP4OX-treated and control groups.

"Trauma patients suffer organ dysfunction from shock and lack of oxygen supply to vital tissues.  Prolonged lactic acidosis, a marker of shock, correlates with a worse outcome and higher mortality rate. This study suggests that MP4OX has the ability to improve oxygen delivery to the body and subsequently reduce organ failure and other complications," said Karim Brohi, Professor of Trauma Sciences at Barts and the London School of Medicine & Dentistry and lead study investigator. "We are excited by the results from this study as they suggest that MP4OX has the potential to
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
2. Sangart, Inc. Completes Series F Funding Round
3. Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
6. Par Pharmaceutical Reports Second Quarter 2008 Results
7. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
8. Pharmos Corporation Reports 2008 Second Quarter Results
9. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
10. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
11. BMP Sunstone Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Pacific ... 2014 Summary Global Markets Direct,s, ,Pacific ... 2014, provides an overview of the Pacific Northwest ... This report provides comprehensive information on the current ... complete with comparative analysis at various stages, therapeutics ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Shimadzu ... extensometer, an easy-to-use and highly precise tool for ... with considerable elongation. With 1000-mm maximum movement distance, ... percent for a gauge length of 10 mm. ... measurement accuracy above 50-mm stroke and within +/- ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Over the ... primarily due to rising R&D budgets and increased acceptance ... fast growing pharmaceutical and biotechnology industries are also catalyzing ... laboratory filtration market is expected to grow at a ... is estimated to be worth $2,532.6 million by 2019. ...
(Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4
... Medicine Project of, Seattle (CHIMPS) Presented at Academic Pediatric Association Conference ... ... CHELMSFORD, Mass., April 22 El Salvador, like many,emerging markets, must ... public concern. This past fall, the El Salvadoran,government threatened to shut ...
... Comprise One of the Main User Groups of febit,s ... Simplified and Automated Microarray Technology, MEDFORD, Mass., and ... will introduce the Geniom RT Analyzer(R) to,the U.S. market at ... Boston., RNA-researchers, one of the main user groups of ...
... Netherlands and SANTA CLARA, Calif., April 22 /PRNewswire/,-- ... evolving field of molecular,diagnostics, and Agilent Technologies, Inc. ... they intend to collaborate to develop new in-vitro,diagnostic ... agreement in,which Agendia products will continue to be ...
Cached Biology Technology:ESA LeadCare(R) System Used to Identify Salvadoran Children with Lead Poisoning 2ESA LeadCare(R) System Used to Identify Salvadoran Children with Lead Poisoning 3ESA LeadCare(R) System Used to Identify Salvadoran Children with Lead Poisoning 4febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress 2febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress 3Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement 2Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement 3
(Date:9/30/2014)... goes wrong with your muscles because of age, disease or ... is. That,s where a new research report published in the ... comes in. In the report, a team of scientists ... help scientists "see" which genes are active in an organ ... activity and that men have approximately 400 more active genes ...
(Date:9/30/2014)... perilous threats in today,s ocean. From overfishing and ... coral ecosystems are disappearing at unprecedented rates around ... corals surrounding the island of Moorea in French ... environment: coral guard-crabs. New research from the National ... Seabird McKeon and the museum,s predoctoral fellow Jenna ...
(Date:9/29/2014)... new study confirms that the exposure to tar tended ... of regular cigarettes. Similarly, exposure to nicotine tended ... popular type of cigarette in several countries around the ... certain toxic chemicals in the smoke of these cigarettes ... lower levels of chemicals in the smoke are not ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Slim cigarette smokers not exposed to more harmful chemicals 2
... function of a newly discovered gene in corn may ... reducing childhood blindness and mortality rates, according to a ... Chair of Translational Genomics and professor of agronomy at ... and particularly orange corn, a type he said likely ...
... of Michigan and Shanghai Jiao Tong University in ... renewable energy and biomedical research projects involving investigators ... renewable-energy program is to develop new technologies that ... climate change. The biomedical collaboration will spur technological ...
... This release is available in French . ... have genetically manipulated rats that can emulate Alzheimer,s disease in ... treatments. Alzheimer,s is a devastating brain condition leading to a ... research mice have been developed in the past, rats are ...
Cached Biology News:Orange corn holds promise for reducing blindness, child death 2U-M joins with Chinese university to jointly fund renewable energy and biomedical research projects 2
Polyclonal Antibody to SHPRH...
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Biotin anti-mouse Ly-49C/F/I/H...
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
Biology Products: